Gujarat Magazine

Pfizer’s Vyndaqel market size expected to increase many folds by 2032, report DelveInsight

 Breaking News
  • No posts were found

Pfizer’s Vyndaqel market size expected to increase many folds by 2032, report DelveInsight

January 24
13:35 2024
Pfizer’s Vyndaqel market size expected to increase many folds by 2032, report DelveInsight
Vyndaqel Market
“Vyndaqel – Market Size, Forecast, and Drug Insight – 2030” report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Vyndaqel in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017–2030 is provided in this report along with a detailed description of the product.

DelveInsight has recently published a report on “Vyndaqel Market Forecast Report” providing an in-depth analysis of the Vyndaqel market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The comprehensive report provides an analysis of Vyndaqel market potential and market share analysis in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) therapeutics space across the 7MM from 2019 to 2032. 

The report also helps you to understand the Vyndaqel clinical and commercial developments along with parameters like the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.

Interested in finding out the projected market size of Vyndaqel by 2032? Visit: Vyndaqel Market Forecast

Vyndaqel Drug Summary

VYNDAQEL and VYNDAMAX are prescription medicines that contain the same active ingredient and are used to treat both the wild-type and hereditary forms of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce death and hospitalization related to heart problems. The clinical studies of VYNDAQEL® (tafamidis meglumine) supported the approval of VYNDAMAX.

VYNDAQEL is taken as four 20-mg capsules once a day. VYNDAMAX 61 mg is a once-daily, single-capsule form of VYNDAQEL that was developed for patient convenience.

In a study, VYNDAMAX 61 mg was shown to work the same way as VYNDAQEL 80 mg.

Stay ahead of the competition by leveraging key insights and evolving trends in the Vyndaqel Vyndaqel Market @ Vyndaqel Market Outlook and Key Assessment

Key Highlights of the Vyndaqel Market Report

  • The report contains forecasted sales evaluation of Vyndaqel for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) till 2032.
  • It provides comprehensive coverage of late-stage emerging therapies for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) treatment.
  • The report also features qualitative and quantitative analysis with analysts, as well as KOL views for Vyndaqel in Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

Why Vyndaqel Market Report?

  • Leading Vyndaqel for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Vyndaqel.
  • A thorough Vyndaqel market forecast will help understand how the drug is competing with other emerging therapies in the therapeutics landscape.
  • It will help to get an analysis of the Vyndaqel clinical trial advancements and the detailed clinical assessment, regulatory, and commercial assessment
  • The report also provides future market assessments for Vyndaqel market for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the 7 Major Markets, advanced qualitative analysis like SWOT, expert analysts’ views, a detailed overview of market competitors, and a short analysis of other emerging therapies in Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

Request the Sample PDF to Learn More About the Key Offerings of the Report @

Related Reports By DelveInsight:

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Outlook and Forecast

“Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Insights, Epidemiology and Market Forecast 2032” report delivers an in-depth understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM), historical and forecasted epidemiology as well as the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan. It also covers the key companies and emerging therapies in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) therapeutics landscape.

Top Services Offered By DelveInsight:

Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States